Scribd
Upload
86 views1 page

Class Indications Available Dosage Form in The Hospital Dosage

Piracetam is an antimyoclonic and nootropic drug used to enhance cognition in the elderly and treat cortical myoclonus and sickle cell anemia. It is available as 400mg and 800mg capsules, 1g/5ml injections, and 20mg/100ml syrup. Dosages range from 1.2-4.8g daily for cognitive disorders to a maximum of 24g daily for cortical myoclonus. Dosage adjustments are needed for renal impairment but not hepatic impairment. Common side effects include weight gain, nervousness, and hyperkinesia.

Uploaded by

Ștefana Stefi
Copyright
© © All Rights Reserved
We take content rights seriously. If you suspect this is your content, claim it here.
Available Formats
Download as PDF, TXT or read online on Scribd
86 views1 page

Class Indications Available Dosage Form in The Hospital Dosage

Piracetam is an antimyoclonic and nootropic drug used to enhance cognition in the elderly and treat cortical myoclonus and sickle cell anemia. It is available as 400mg and 800mg capsules, 1g/5ml injections, and 20mg/100ml syrup. Dosages range from 1.2-4.8g daily for cognitive disorders to a maximum of 24g daily for cortical myoclonus. Dosage adjustments are needed for renal impairment but not hepatic impairment. Common side effects include weight gain, nervousness, and hyperkinesia.

Uploaded by

Ștefana Stefi
Copyright
© © All Rights Reserved
We take content rights seriously. If you suspect this is your content, claim it here.
Available Formats
Download as PDF, TXT or read online on Scribd
You are on page 1/ 1

PIRACETAM:

Class: Antimyoclonic, Nootropic

Indications: Enhance cognition in the elderly; cortical myoclonus; sickle cell anemia

Available dosage form in the hospital: CAP (400MG, 800MG), 1G /5ML INJ, 20MG/100ML SYRP

Dosage:
Cognitive disorders: Oral, I.V.: Dosage range: 1.2-4.8 g daily administered in 2-3 divided doses. May
start at higher end of range according to initial severity of symptoms.
Cortical myoclonus, adjunctive: Oral, I.V.: Initial: 7.2 g daily administered in 2-3 divided doses. May
increase total daily dose by 4.8 g every 3-4 days if needed (maximum daily dose: 24 g). Consider
dosage reduction or gradual withdrawal of piracetam therapy every 6 months if symptoms are
controlled; reduce daily dose by 1.2 g every 2 days (every 3-4 days for patients with Lance-Adams
syndrome).
Vertigo: Oral, I.V.: 2.4-4.8 g daily administered in 2-3 divided doses

Hepatic impairment:
No dosage adjustment necessary.

Renal impairment:
Clcr >80 mL/minute: No dosage adjustment necessary.
Clcr 50-80 mL/minute: Initial and maximum dose: Decrease to 2/3 of the normal daily dose administered
in 2-3 divided doses.
Clcr 30 to <50 mL/minute: Initial and maximum dose: Decrease to 1/3 of the normal daily dose
administered in 2 divided doses.
Clcr 20 to <30 mL/minute: Decrease to 1/6 of the normal daily dose administered once daily.
Clcr <20 mL/minute: Use is contraindicated.

Common side effect:


Weight gain, nervousness, hyperkinesia; less commonly drowsiness, depression, asthenia,; also reported
abdominal pain, nausea, vomiting, diarrhoea, headache, anxiety, confusion, hallucination, vertigo,
ataxia, insomnia, and rash

Pregnancy Risk Factor :


Adverse events have not been observed in animal reproduction studies. Piracetam crosses placental
barrier with neonatal levels ~70% to 90% of maternal levels. In general, higher risk of teratogenic
effects may be associated with anticonvulsant polytherapy compared to monotherapy (Morrow, 2006).

You might also like